Get startedLog in
    Picture of Celldex Therapeutics logo

    CLDX — Celldex Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapMomentum Trap
    All News

    Brief: Celldex Announces First Patient Dosed In Phase 1 Healthy Volunteer Study Of CDX-622

    Picture of Celldex Therapeutics logoCelldex Therapeutics
    20/11/2024 13:07
    Nov 20 (Reuters) - Celldex Therapeutics Inc  CLDX.O :
    * CELLDEX ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 HEALTHY
VOLUNTEER STUDY OF CDX-622, A BISPECIFIC ANTIBODY, FOR THE
TREATMENT OF INFLAMMATORY DISEASES
    * CELLDEX THERAPEUTICS INC - SUBCUTANEOUS FORMULATION TO BE
ADDED
TO STUDY IN 2025

Source text:  ID:nGNX5X6TYF 
Further company coverage:  CLDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Celldex Therapeutics

    See all news